CARE Ratings is a leading credit rating agency of India. The Company provides various credit ratings that helps corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own riskreturn expectations.(Source : 202003-01 Annual Report Page No:134)
The company possesses a wide moat derived from a regulatory license and high switching costs, as credit ratings are mandatory for debt issuance and deeply embedded in institutional investment mandates. This is corroborated by exceptionally high operating margins (48% in standalone ratings) and a dominant position as the second-largest player in a consolidated industry.
Management maintains a conservative, debt-free balance sheet with high dividend payouts (INR 22/share in FY26). They have successfully turned around previously loss-making non-rating subsidiaries and are selectively investing in global expansion (GIFT City, Africa) while maintaining a disciplined, value-oriented filter for acquisitions.
The investment collapsed as the credit rating industry underwent a structural shift toward commoditization, where bank loan ratings—already a high-volume but low-margin segment—became the dominant revenue driver while high-margin bond ratings stagnated. Regulatory scrutiny intensified following the resolution of historical litigation, leading to a loss of institutional trust and a subsequent migration of issuers to larger global competitors. The company's attempt to diversify into international markets and non-rating subsidiaries failed to achieve the necessary scale to offset the margin compression in the core domestic business, resulting in a permanent derating of the stock as the once-vaunted 48% margins reverted to the industry mean.
RichFakir rates CARE Ratings Ltd's business quality as wonderful — 74/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as wide.
On our model, CARE Ratings Ltd is trading about 77% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on CARE Ratings Ltd is: Watch — wait for price. A wonderful business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of CARE Ratings Ltd's fair value is about ₹923 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →